机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.首都医科大学附属北京同仁医院临床科室耳鼻咽喉-头颈外科[2]Beijing Institute of Otolaryngology, Beijing, China.首都医科大学附属北京同仁医院研究所耳鼻咽喉科研究所[3]Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.首都医科大学附属同仁医院[4]Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, 100730, China.[5]Department of Urology, The Second Affiliated Hospital of Jinan University, Shenzhen People’s Hospital, Shenzhen, Guangdong, China.深圳市康宁医院深圳市人民医院深圳医学信息中心[6]Neurontechnology, Shenzhen, Guangdong, China.[7]Department of Cell Biology and Medical Genetics, Shenzhen University Medical School, Shenzhen, 518060, China.深圳市康宁医院深圳医学信息中心[8]Department of Physiology, School of Basic Medical Sciences, Shenzhen University Health Sciences Center, Shenzhen, 518060, China.深圳市康宁医院深圳医学信息中心
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients.
基金：
This work was supported by the Capital Characteristic Clinical Application Research Program of the Beijing
Municipal Science and Technology Commission (Z141107002514003), National Natural Science Foundation of
China (81473499), and the Shenzhen Commission of Science and Innovation Program (JCYJ201607115221141,
JCYJ20170307095441539, GCZX20150430016165448).
第一作者机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing, China.[3]Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
通讯作者：
通讯机构：[1]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing, China.[3]Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
推荐引用方式(GB/T 7714)：
Qi Zhong,Jugao Fang,Zhigang Huang,et al.A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma[J].SCIENTIFIC REPORTS.2018,8:doi:10.1038/s41598-018-31027-y.
APA：
Qi Zhong,Jugao Fang,Zhigang Huang,Yifan Yang,Meng Lian...&Yingduan Cheng.(2018).A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.SCIENTIFIC REPORTS,8,
MLA：
Qi Zhong,et al."A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma".SCIENTIFIC REPORTS 8.(2018)
